Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).  In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at least 15 letters of vision from baseline, compared to 12.3 percent of patients receiving sham injections (p<0.0001), the primary endpoint of the study.  Patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 17.3 letters of vision compared to a mean loss of 4.0 letters with sham injections (p<0.001), a secondary endpoint.  The second Phase 3 study, GALILEO, is currently ongoing and is led by Bayer HealthCare.

VEGF Trap-Eye was generally well tolerated and the most common adverse events were those typically associated with intravitreal injections or the underlying disease.  A total of 114 patients were randomized to receive VEGF Trap-Eye and 73 patients to the control arm.  Serious ocular adverse events in the VEGF Trap-Eye group were uncommon (3.5%) and were more frequent in the control group (13.5%).  The incidence of non-ocular serious adverse events was generally well-balanced between the treatment arms.  There were no deaths among the 114 patients treated with VEGF Trap-Eye and two in the 73 (2.7%) patients treated with sham injections.

"In the COPERNICUS trial, patients treated with VEGF Trap-Eye experienced a marked improvement in vision," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories.  "If these results are confirmed by data from the GALILEO study, expected in the second quarter of 2
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
(Date:7/24/2014)... In a recent report by CBS News, the ... end to criminal penalties associated with possession of small amounts ... reform in Washington DC, giving it one of the most ... penalties for possession of one ounce of marijuana or less ... more than an ounce of marijuana remain criminal offenses under ...
(Date:7/24/2014)... circumcisions that involves direct oral suction is a likely ... transmissions documented in infants between 1988 and 2012, a ... and published online in the Journal of the ... from Penn,s Center for Evidence-based Practice , identified ... , The practiceknown as metzitzah b,pehand its link to ...
(Date:7/24/2014)... New research from Penn Medicine shows that incisionless ... of hospital stay by 30 percent and has ... compared with conventional transfemoral TAVR, which requires an ... available in the current issue of Circulation: ... of the aortic valve without a traditional open-heart ...
(Date:7/24/2014)... Papillomavirus Vaccination (HPV) even after becoming sexually active ... than those who were never vaccinated. These findings ... . , Researchers from Boston University School ... a cross-sectional study of 235 women age 21 ... status and demographic and behavioral characteristics were self-reported ...
(Date:7/24/2014)... R.I. Lynn E. Taylor, M.D., director of ... in the July, 2014 Rhode Island Medical ... that eliminating hepatitis c virus infection (hep c ... enhance capacity to address other health challenges, and ... in the United States, Taylor says, include lack ...
Breaking Medicine News(10 mins):Health News:Washington D.C. Decriminalizes Marijuana 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... March 17 Researchers will unveil a,new ... been shown in numerous,published studies to help ... the performance of daily living tasks essential ... Corporation, a San,Francisco-based neuroscience company, will introduce ...
... is the Largest Prospective Trial to Examine Asthma Outcomes Based on ... ... N.C. and PHILADELPHIA, March 16 ,Data presented today by GlaxoSmithKline showed ... in asthma patients did not,lead to different responses to Advair Diskus(R) ...
... is the daily,"Profile America" feature from the U.S. Census ... Profile America -- Saturday, March 15th. If you,re ... it,s time to pause,stand back and reflect that there ... events celebrating the value of laughter and those who ...
... Coronary Heart Disease, WASHINGTON, March 14 ... the decision by the Centers,for Medicare and Medicaid ... coverage,for cardiac computed tomographic angiography (CTA) for the ... its national coverage decision for this important,tool for ...
... (March 13, 2008) The American Academy of Cosmetic ... its 2007 Procedural Data. This information is collected by ... that sclerotherapy, the standard treatment for spider and varicose ... surgical procedure, due in large part to men. ...
... found it made difference when disease moved from colon, ... certain patients with cancer that has spread to the ... surgery combined with a special kind of chemotherapy can ... The findings are from one of two Wake Forest ...
Cached Medicine News:Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 2Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 4Health News:SCAI Applauds CMS Decision to Continue Coverage of Cardiac CT Scans 2Health News:Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining 2
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: